THE FACTORS AFFECTING THE DROPOUT OF PERITONEAL DIALYSIS IN PATIENTS REFERRED TO A DIALYSIS CENTER IN NORTHWEST IRAN
Main Article Content
Keywords
Peritoneal dialysis, end-stage renal disease, hemodialysis, risk factors
Abstract
Introduction: Peritoneal dialysis (PD) is a type of dialysis that is more affordable than other methods. This study aimed to determine the factors affecting the dropout of PD in patients referred to a dialysis center in northwest Iran.
Material and Methods: This retrospective study was conducted with census sampling on 719 end-stage renal disease (ESRD) patients who underwent PD in Imam Reza hospital in Tabriz between 2001 and 2022. After determining the frequency distribution of factors for dropping out of PD in patients was evaluated.
Results: Most causes of PD dropout were related to death (40.5%), kidney transplantation (27.3%), peritonitis (11.6%), catheter failure (6.8%), insufficient dialysis (5.7%), intolerance (4.6%), renal function reversal (0.6%), severe disease, Probably, they have played an important role in improving the condition of peritoneal dialysis patients during these years. (0.1%), and exit site infection (0.1%) respectively. The duration of PD was longer in people who did not smoke than others (P=0.004). The lowest mean course of PD was from 2006 to 2009 (P=0.009).
Conclusion: Death, kidney transplantation, peritonitis, catheter failure, insufficient dialysis condition, and intolerance are the most common causes of dropout among PD patients. Not tobacco use may help the maintenance (more extended duration usage) of PD in patients. Also, the mean duration of PD in the years 2018 to 2022 was better than previous years, which is probably a sign of improvement in the quality of dialysis center performance.
References
2. Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022 Jun;18(6):378-395. doi: 10.1038/s41581-022-00542-7.
3. Mbeje PN. Factors affecting the quality of life for patients with end-stage renal disease on dialysis in KwaZulu-Natal province, South Africa: A descriptive survey. Health SA. 2022 Dec 7;27:1932. doi: 10.4102/hsag.v27i0.1932.
4. Mushtaque I, Awais-E-Yazdan M, Zahra R, Anas M. Quality of Life and Illness Acceptance among End-Stage Renal Disease (ESRD) Patients on Hemodialysis: The Moderating Effect of Death Anxiety during COVID-19 pandemic. Omega (Westport). 2022 Mar 7:302228221075202. doi: 10.1177/00302228221075202.
5. Moreno Velásquez I, Tribaldos Causadias M, Valdés R, Gómez B, Motta J, Cuero C, et al. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study. BMJ Open. 2019 May 27;9(5):e027229. doi: 10.1136/bmjopen-2018-027229.
6. Alloatti S, Manes M, Paternoster G, Gaiter AM, Molino A, Rosati C. Peritoneal dialysis compared with hemodialysis in the treatment of end-stage renal disease. J Nephrol. 2000 Sep-Oct;13(5):331-42. PMID: 11063136.
7. Yang F, Khin LW, Lau T, Chua HR, Vathsala A, Lee E, et al. Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease. PLoS One. 2015 Oct 7;10(10):e0140195. doi: 10.1371/journal.pone.0140195.
8. Herrera L, Gil F, Sanabria M. Hemodialysis vs Peritoneal Dialysis: Comparison of Net Survival in Incident Patients on Chronic Dialysis in Colombia. Can J Kidney Health Dis. 2021 Mar 1;8:2054358120987055. doi: 10.1177/2054358120987055.
9. Salzer WL. Peritoneal dialysis-related peritonitis: challenges and solutions. Int J Nephrol Renovasc Dis. 2018 Jun 11;11:173-186. doi: 10.2147/IJNRD.S123618.
10. Ajayi S, Raji Y, Bello T, Arije A. Challenges and possible solutions to peritoneal dialysis use in Nigeria. Pan Afr Med J. 2020 Apr 28;35:138. doi: 10.11604/pamj.2020.35.138.21066.
11. Li M, Yan J, Zhang H, Wu Q, Wang J, Liu J, et al. Analysis of outcome and factors correlated with maintenance peritoneal dialysis. J Int Med Res. 2019 Oct;47(10):4683-4690. doi: 10.1177/0300060519862091.
12. Luo Q, Xia X, Lin Z, Lin J, Yang X, Huang F, et al. Very early withdrawal from treatment in patients starting peritoneal dialysis. Ren Fail. 2018 Nov;40(1):8-14. doi: 10.1080/0886022X.2017.1419965.
13. Li L, Pei H, Liu Z, Zhang J. Analysis of risk factors and construction of prediction model of drop out from peritoneal dialysis. Medicine (Baltimore). 2021 Jan 22;100(3):e24195. doi: 10.1097/MD.0000000000024195.
14. Torres H, Naljayan M, Frontini M, Aguilar E, Barry S, Reisin E. Evaluating Factors Contributing to Dropout in a Large Peritoneal Dialysis Program. Am J Med Sci. 2021 Jan;361(1):30-35. doi: 10.1016/j.amjms.2020.06.030.
15. Zhang L, Lee WC, Wu CH, Kuo LC, Yang HT, Moi SH, et al. Importance of non-medical reasons for dropout in patients on peritoneal dialysis. Clin Exp Nephrol. 2020 Nov;24(11):1050-1057. doi: 10.1007/s10157-020-01948-y.
16. See EJ, Johnson DW, Hawley CM, Pascoe EM, Badve SV, Boudville N, et al. Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. Am J Kidney Dis. 2018 Aug;72(2):188-197. doi: 10.1053/j.ajkd.2017.10.019.
17. Kolesnyk I, Dekker FW, Boeschoten EW, Krediet RT. Time-dependent reasons for peritoneal dialysis technique failure and mortality. Perit Dial Int. 2010 Mar-Apr;30(2):170-7. doi: 10.3747/pdi.2008.00277.
18. Descoeudres B, Koller MT, Garzoni D, Wolff T, Steiger J, Schaub S, et al. Contribution of early failure to outcome on peritoneal dialysis. Perit Dial Int. 2008 May-Jun;28(3):259-67. PMID: 18474918.
19. Kang M, Kim YL, Kang E, Ryu H, Kim YC, Kim DK, Lee H, Han SS, Joo KW, Kim YS, Ahn C, Oh KH. Evolving outcomes of peritoneal dialysis: secular trends at a single large center over three decades. Kidney Res Clin Pract. 2021 Sep;40(3):472-483. doi: 10.23876/j.krcp.21.020.
20. Chaudhary K. Peritoneal Dialysis Drop-out: Causes and Prevention Strategies. Int J Nephrol. 2011;2011:434608. doi: 10.4061/2011/434608.
21. Piarulli P, Vizzardi V, Alberici F, Riva H, Aramini M, Regusci L, Cippà P, Bellasi A. Peritoneal dialysis discontinuation: to the root of the problem. J Nephrol. 2023 Sep;36(7):1763-1776. doi: 10.1007/s40620-023-01759-w.
22. Fakhrioliaei A, Abedinifar F, Salehi Darjani P, Mohammadi-Khanaposhtani M, Larijani B, Ahangar N, Mahdavi M. Hybridization of the effective pharmacophores for treatment of epilepsy: design, synthesis, in vivo anticonvulsant activity, and in silico studies of phenoxyphenyl-1, 3, 4-oxadiazole-thio-N-phenylacetamid hybrids. BMC chemistry. 2023 Jul 17;17(1):80.
23. Mollazadeh M, Azizian H, Fakhrioliaei A, Iraji A, Avizheh L, Valizadeh Y, Zomorodian K, Elahi F, Moazzam A, Kazemzadeh H, Amanlou M. Different barbiturate derivatives linked to aryl hydrazone moieties as urease inhibitors; design, synthesis, urease inhibitory evaluations, and molecular dynamic simulations. Medicinal Chemistry Research. 2023 May;32(5):930-43.
24. Safapoor S, Halimi M, Ghomi MK, Noori M, Dastyafteh N, Javanshir S, Hosseini S, Mojtabavi S, Faramarzi MA, Nasli-Esfahani E, Larijani B. Synthesis, ADMT prediction, and in vitro and in silico α-glucosidase inhibition evaluations of new quinoline–quinazolinone–thioacetamides. RSC Advances. 2023;13(28):19243-56.
25. Ghalehbandi M, Khosravifar S, Aloosh O, Rahimi‐Golkhandan A, Abounoori M, Aloosh A, Afshar H, Khosravifar S. The association between sleep quality, health status and disability due to breathlessness in chronic obstructive pulmonary disease patients. The Clinical Respiratory Journal. 2021 Nov;15(11):1168-74.
26. Omranifard V, Abounoori M, Babakhanian M, Ebrahimi A, Akouchekian S, Shafiei K, Khosravifar S. Translation and psychometric properties of the Persian version of the Health of the Nation Outcome Scales for Elderly People (HoNOS65+). Aging Medicine. 2021 Jun;4(2):135-45.
27. Zhang L, Pakmehr SA, Shahhosseini R, Hariri M, Fakhrioliaei A, Karkon Shayan F, Xiang W, Karkon Shayan S. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment. Medical Oncology. 2023 Dec 8;41(1):8.
28. Doraghi F, Pegah Aledavoud S, Fakhrioliaei A, Larijani B, Mahdavi M. Ring‐Opening Cross‐Coupling/Cyclization Reaction of Cyclopropanols with Organic Compounds. ChemistrySelect. 2023 Aug 31;8(32):e202301438.
29. Shayan SK, Aliashrafzadeh H, Rezayitalab F, Sobhani M, Zarei M. Comparison of the Outcome of Altplas Administration after Acute Ischemic Stroke in Patients Over 80 Years and Under 80 Years Admitted. Journal of Pharmaceutical Negative Results. 2022 Sep 22:684-8.
30. Shayan SK, Nasrollahi E, Bahramvand Y, Zarei M, Atarodi A, Farsi Y, Tavakolizadeh M, Shirvaliloo M, Abbasifard M, Jamialahmadi T, Banach M. Percutaneous Coronary Intervention Associated with a Higher Risk of Hypoxemia and COVID-19 Severity. Current Medicinal Chemistry. 2024.
31. Karkon-Shayan S, Aliashrafzadeh H, Dianat-Moghadam H, Rastegar-Pouyani N, Majidi M, Zarei M, Bahramvand Y, Babaniamansour S, Jafarzadeh E. Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths. Acta Histochemica. 2023 Aug 1;125(6):152058.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Mohammadreza Ardalan
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Mohammadreza Moslemi
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Sepideh Zununi Vahed
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Sahar Heydari
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran